WO2011020319A8 - 调节血糖血脂的融合蛋白及其制备方法和应用 - Google Patents

调节血糖血脂的融合蛋白及其制备方法和应用 Download PDF

Info

Publication number
WO2011020319A8
WO2011020319A8 PCT/CN2010/071026 CN2010071026W WO2011020319A8 WO 2011020319 A8 WO2011020319 A8 WO 2011020319A8 CN 2010071026 W CN2010071026 W CN 2010071026W WO 2011020319 A8 WO2011020319 A8 WO 2011020319A8
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
lipid
preparation
plasma glucose
protein regulating
Prior art date
Application number
PCT/CN2010/071026
Other languages
English (en)
French (fr)
Other versions
WO2011020319A1 (zh
Inventor
范开
赵志全
张淳
陈勇
罗华
杨黎
刘洪洪
Original Assignee
重庆富进生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆富进生物医药有限公司 filed Critical 重庆富进生物医药有限公司
Priority to US13/391,226 priority Critical patent/US8809499B2/en
Priority to CN2010800369675A priority patent/CN102770538A/zh
Priority to EP10809452.5A priority patent/EP2468858B1/en
Publication of WO2011020319A1 publication Critical patent/WO2011020319A1/zh
Publication of WO2011020319A8 publication Critical patent/WO2011020319A8/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/CN2010/071026 2009-08-20 2010-03-12 调节血糖血脂的融合蛋白及其制备方法和应用 WO2011020319A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/391,226 US8809499B2 (en) 2009-08-20 2010-03-12 Fusion protein of human fibroblast growth factor-21 and exendin-4
CN2010800369675A CN102770538A (zh) 2009-08-20 2010-03-12 调节血糖血脂的融合蛋白及其制备方法和应用
EP10809452.5A EP2468858B1 (en) 2009-08-20 2010-03-12 Fusion protein regulating plasma glucose and lipid, its preparation method and use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910104650XA CN101993485B (zh) 2009-08-20 2009-08-20 促胰岛素分泌肽类似物同源二聚体及其用途
CN200910104650.X 2009-08-20
CN200910104653.3 2009-08-20

Publications (2)

Publication Number Publication Date
WO2011020319A1 WO2011020319A1 (zh) 2011-02-24
WO2011020319A8 true WO2011020319A8 (zh) 2012-03-15

Family

ID=43606593

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2010/071026 WO2011020319A1 (zh) 2009-08-20 2010-03-12 调节血糖血脂的融合蛋白及其制备方法和应用
PCT/CN2010/071036 WO2011020320A1 (zh) 2009-08-20 2010-03-15 促胰岛素分泌肽类似物同源二聚体及其制备方法与用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/071036 WO2011020320A1 (zh) 2009-08-20 2010-03-15 促胰岛素分泌肽类似物同源二聚体及其制备方法与用途

Country Status (4)

Country Link
US (2) US8809499B2 (zh)
EP (1) EP2479193B1 (zh)
CN (1) CN101993485B (zh)
WO (2) WO2011020319A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109836504A (zh) * 2017-11-24 2019-06-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
CN103087174B (zh) * 2011-11-03 2015-11-18 华东师范大学 一种glp-1衍生物dlg3312及其固相化学合成方法
TWI560202B (en) * 2011-12-22 2016-12-01 Pfizer Anti-diabetic compounds
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
SG11201500682WA (en) * 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
JP6403685B2 (ja) 2012-12-27 2018-10-17 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104277113B (zh) * 2013-07-08 2017-09-26 中国人民解放军军事医学科学院毒物药物研究所 抑制hiv感染的二价多肽
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
RU2016137264A (ru) * 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN105017408B (zh) * 2014-04-30 2019-11-05 重庆派金生物科技有限公司 聚乙二醇化血小板生成素模拟肽同源四聚体及其用途
CN105085661A (zh) * 2014-05-04 2015-11-25 重庆派金生物科技有限公司 人胰高血糖素类似肽2（glp-2c）聚乙二醇化同源二聚体及其用途
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104311656B (zh) * 2014-10-14 2017-04-05 哈尔滨博翱生物医药技术开发有限公司 cFGF‑21蛋白及其在治疗类风湿关节炎中的应用
RU2729161C2 (ru) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN104558150B (zh) * 2014-11-04 2017-12-15 广东药学院 一类生长激素释放激素类似肽及其在制备治疗不孕不育药物中的应用
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10744185B2 (en) 2015-11-09 2020-08-18 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of pruritus
KR20170080526A (ko) * 2015-12-31 2017-07-10 한미약품 주식회사 Fgf21 아날로그, fgf21 결합체, 및 이의 용도
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
CN107561168A (zh) * 2016-06-30 2018-01-09 山东新时代药业有限公司 一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
KR20180052545A (ko) * 2016-11-10 2018-05-18 주식회사유한양행 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
CN108226362B (zh) * 2016-12-21 2021-05-25 鲁南制药集团股份有限公司 一种聚乙二醇化促胰岛素分泌肽类似物中间体的分析检测方法
RU2019122785A (ru) 2016-12-22 2021-01-22 Санофи Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
EP3592758A4 (en) * 2017-03-06 2021-04-14 Synvitrobio, Inc. PROCESSES AND SYSTEMS FOR CELL-FREE BIO-DISCOVERY OF NATURAL PRODUCTS
WO2018194413A1 (en) * 2017-04-21 2018-10-25 Yuhan Corporation Method for producing dual function proteins and its derivatives
CN107253985B (zh) * 2017-06-23 2021-03-09 中国药科大学 一类长效化降糖肽的设计及其应用
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
SG11202001772SA (en) * 2017-09-21 2020-04-29 Merck Patent Gmbh Fusion protein comprising an fgf-18 moiety
JP2021514678A (ja) 2018-03-06 2021-06-17 ペップバックス・インコーポレイテッド 核酸分子およびそれを使用する方法
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20070161087A1 (en) 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
CN1802386B (zh) 2003-06-12 2010-12-15 伊莱利利公司 Glp-1类似物融合蛋白质
ES2298785T3 (es) 2003-06-12 2008-05-16 Eli Lilly And Company Proteinas de fusion.
CA2548179A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
EP1756160B1 (en) * 2004-06-18 2013-08-14 IPF Pharmaceuticals GmbH Oligomeric peptides and their use for the treatment of hiv infections
EP2161281A1 (en) 2004-09-02 2010-03-10 Eli Lilly & Company Muteins of fibroblast growth factor 21
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
EP1863537A2 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
PL1881850T3 (pl) * 2005-05-13 2011-03-31 Lilly Co Eli Pegylowane związki GLP-1
PL1767545T3 (pl) * 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
TWM317024U (en) 2006-07-25 2007-08-11 Longtech Systems Corp Brightness improved structure of lateral backlight for LCD
KR20150116465A (ko) * 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
ES2646614T3 (es) * 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
CA2702289A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
CN100587073C (zh) * 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109836504A (zh) * 2017-11-24 2019-06-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白

Also Published As

Publication number Publication date
EP2479193A1 (en) 2012-07-25
EP2479193B1 (en) 2015-02-18
CN101993485A (zh) 2011-03-30
US8557771B2 (en) 2013-10-15
WO2011020319A1 (zh) 2011-02-24
CN101993485B (zh) 2013-04-17
EP2479193A4 (en) 2013-09-25
US20120238496A1 (en) 2012-09-20
US20120277154A1 (en) 2012-11-01
WO2011020320A1 (zh) 2011-02-24
EP2479193A9 (en) 2013-01-02
US8809499B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
PH12016500606A1 (en) Insulin preparations containing methionine
WO2007124461A3 (en) Glp-1 compounds
WO2007120936A3 (en) Use.of vildagliptin for the treatment of diabetes
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
MY160153A (en) Process for the preparation of plant extracts for treating skin disorders and enhancing healing of wounds
MX2013013242A (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
WO2007098479A3 (en) Localized insulin delivery for bone healing
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
HK1076721A1 (en) A chinese traditional medical composition for treating diabetes and method for preparing the same
WO2009035534A3 (en) Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
ZA201000990B (en) Herbal formulations for controlling blood glucose levels in patients with diabetes
WO2011056447A3 (en) Methods and kits for preventing hypoglycemia
WO2007126792A3 (en) Use of ghrelin splice variant for treating high cholesterol levels or high plasma glucose levels and releated diseases
WO2009133099A3 (en) Insulin precursors for oral diabetes treatment
ZA201007061B (en) Pyridopyrazinones derivatives insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
WO2006004696A3 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
ZA201008505B (en) Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
WO2005039627A3 (en) Therapeutic applications for c-peptide
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"
WO2006096079A3 (en) Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus.
WO2008130591A3 (en) Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
WO2006113220A3 (en) Transgenic mammals expressing human preproinsulin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080036967.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809452

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13391226

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010809452

Country of ref document: EP